Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking method to diabetes management. These innovative drugs function by mimicking the inherent actions of GLP-1, a hormone produced by the gut in response to consumption. By stimulating GLP-1 receptors in the pancreas, these substances increase insulin release and suppress gl

The management of diabetes is with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant recognition. These medications offer promising approaches for controlling blood sugar levels and may improve the lives of individuals living with diabetes. This novel class of